Krishna Institute of Medical Sciences share news, announcements and annual reports
NSE: KIMSBSE: 543308Healthcare ServicesSmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹704.60.
29 Oct: open ₹705.00, high ₹718.65, low ₹700.50
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹29,505 Cr285th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 144.28
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.13
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,22,18047.5% delivered
Krishna Institute of Medical Sciences analyst meets
130 filed, newest first. Page 2 of 3.
Feb 2025
5 Feb · Analysts
Jan 2025
31 Jan · Analysts
8 Jan · Analysts
7 Jan · Analysts
1 Jan · Analysts
Dec 2024
10 Dec · Analysts
7 Dec · Analysts
6 Dec · Analysts
6 Dec · Analysts
Nov 2024
29 Nov · Analysts
29 Nov · Analysts
27 Nov · Analysts
26 Nov · Analysts
14 Nov · Analysts
14 Nov · Analysts
4 Nov · Analysts
Sep 2024
25 Sep · Analysts
16 Sep · Analysts
Aug 2024
14 Aug · Analysts
2 Aug · Analysts
Jun 2024
9 Jun · Analysts
9 Jun · Analysts
5 Jun · Analysts
5 Jun · Analysts
5 Jun · Analysts
3 Jun · Analysts
3 Jun · Analysts
3 Jun · Analysts
May 2024
11 May · Analysts
Mar 2024
21 Mar · Analysts
21 Mar · Analysts
Feb 2024
8 Feb · Analysts
8 Feb · Analysts
8 Feb · Analysts
Jan 2024
30 Jan · Analysts
File name: “Investorcall050224”
Dec 2023
Nov 2023
3 Nov · Analysts
Sep 2023
2 Sep · Analysts
Aug 2023
12 Aug · Analysts
1 Aug · Analysts
Jun 2023
17 Jun · Analysts
May 2023
17 May · Analysts
File name: “Intimationinvestorcall”
Mar 2023
21 Mar · Analysts
13 Mar · Analysts
Feb 2023
15 Feb · Analysts
8 Feb · Analysts
Dec 2022
13 Dec · Analysts
7 Dec · Analysts
7 Dec · Analysts
Nov 2022
30 Nov · Analysts